新的低分子型肝素正使用于临床,在预防深部静脉血栓形成方面具有良好的效果。据Kakkar指出,低分子型肝素要比标准规格肝素更有效,其诱发出血并发症的危险也较低,且有较高的生物利用度,每天只需注射1次。肝素有抗血栓和抗凝血的双重作用。低分子量部分被认为有选择性的抗血栓作用,故此和肝素联合使用能减少出血的危险。 Kakkar教授尚认为低分子量肝素将成为预防深部静脉血栓形成的标准治疗。在 The new low-molecular-weight heparin is being used clinically, with good results in the prevention of deep venous thrombosis. According to Kakkar, low molecular weight heparins are more effective than standard heparin and have a lower risk of haemorrhagic complications and higher bioavailability with only 1 injection per day. Heparin has the dual role of antithrombotic and anticoagulant. Low-molecular-weight fractions are thought to have a selective anti-thrombotic effect, so the combination with heparin reduces the risk of bleeding. Professor Kakkar still believes that low molecular weight heparin will become the standard treatment to prevent deep venous thrombosis. in